Jobs
岗位职责:
- 参与搭建微生物检测平台,完成方法、设备、公用系统的验证;
- 参与对公用系统进行监控,组织对微生物检测以及公用系统偏差的调查;
- 参与微生物小组的项目检测工作,包括原液和制剂的放行,中间品的控制,原辅料和包材的入厂检测;
- 参与菌种鉴定库以及环境菌株库的建立;
- 参与微生物污染事件的调查与分析;
- 负责监督审核记录、数据分析、报告和存档工作;
- 负责审核部门相关文件的起草工作、检验数据的定期回顾。负责微生物所用的菌种的复苏、传代、使用、储存、处理等工作;
- 负责微生物仪器设备的验证;
- 领导安排的其它任务。
任职要求:
- 本科及以上学历,微生物学、生物学等相关专业;
- 至少3年及以上微生物检测、环境监测经验,有无菌制剂产品相关经历的,优先考虑;
- 熟悉中国药典,GMP指南,ICH,USP等各国关于微生物的法规和指南等;
- 了解无菌、微限及细菌内毒素检测方法及原理,有微生物相关的异常处理能力;了解微生物生长特点的,优先考虑;
- 能在GMP环境中独立执行分析工作,并最大限度地减少实验室误差;
- 英语看说写熟练;
- 具备良好的职业素养和团队协助能力;
- 熟练使用 MS-Word, MS-Excel, MS-Outlook等办公软件。
Total Views
0
Apply Clicks
0
Weekly mock applicants
0
Bookmarks
0
Similar jobs
About BioNTech

BioNTech
PublicBioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
1,001-5,000
Employees
Mainz that develops immunotherapies
Headquarters
$21.7B
Valuation
Reviews
4.0
10 reviews
Work-life balance
2.5
Compensation
3.8
Culture
4.2
Career
3.5
Management
3.2
75%
Recommend to a friend
Pros
Innovative and cutting-edge projects
Great team and collaborative environment
Excellent benefits and flexible schedule
Cons
Long working hours and high workload
Fast-paced and high-pressure environment
Management and communication issues
Salary Ranges
70 data points
L2
L3
L4
L5
L6
Mid/L4
Intern
L2 · Data Scientist L2
0 reports
$53,767
total per year
Base
$21,507
Stock
$26,884
Bonus
$5,377
$37,637
$69,897
Interview experience
1 interviews
Difficulty
3.0
/ 5
Duration
14-28 weeks
Interview process
1
Application Review
2
HR Screen
3
Hiring Manager Interview
4
Panel Interview
5
Final Interview
6
Offer
Common questions
Behavioral/STAR
Technical Knowledge
Past Experience
Culture Fit
Problem Solving
News & Buzz
BioNTech’s BNT323 Achieves Strong Phase 2 Response Rates in Endometrial Cancer - Oncodaily
Oncodaily
News
·
Today
BioNTech And Boehringer Trial Adds Dimension To Small Cell Lung Cancer Story - simplywall.st
simplywall.st
News
·
3d ago
Biontech prepares FDA application after strong phase II results in endometrial cancer - medwatch.com
medwatch.com
News
·
6d ago
BioNTech and DualityBio report positive data for trastuzumab pamirtecan - Clinical Trials Arena
Clinical Trials Arena
News
·
6d ago




